Dermira Inc (DERM) Given Average Recommendation of “Buy” by Analysts

Dermira Inc (NASDAQ:DERM) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $17.75.

A number of equities analysts have commented on DERM shares. BidaskClub lowered Dermira from a “buy” rating to a “hold” rating in a research note on Friday, August 17th. Cantor Fitzgerald restated a “buy” rating and set a $20.00 price objective on shares of Dermira in a research note on Wednesday, September 5th. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research note on Monday, August 13th. ValuEngine upgraded Dermira from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Finally, Mizuho restated a “hold” rating and set a $10.00 price objective on shares of Dermira in a research note on Tuesday, October 2nd.

Shares of NASDAQ DERM traded down $0.17 during trading hours on Friday, reaching $12.76. 315,408 shares of the stock were exchanged, compared to its average volume of 513,776. The firm has a market cap of $536.25 million, a P/E ratio of -2.91 and a beta of 0.96. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 2.49. Dermira has a 52 week low of $6.98 and a 52 week high of $31.42.

Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($0.57) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.57). Dermira had a negative return on equity of 128.21% and a negative net margin of 761.87%. The firm had revenue of $39.08 million for the quarter, compared to analyst estimates of $39.00 million. Analysts forecast that Dermira will post -5.46 EPS for the current year.

In other Dermira news, Director Matthew K. Fust sold 4,000 shares of the firm’s stock in a transaction on Friday, October 19th. The stock was sold at an average price of $13.75, for a total transaction of $55,000.00. Following the transaction, the director now owns 14,051 shares in the company, valued at approximately $193,201.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 14.80% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Xact Kapitalforvaltning AB acquired a new stake in shares of Dermira in the 2nd quarter valued at $106,000. Barclays PLC boosted its holdings in shares of Dermira by 276.7% in the 1st quarter. Barclays PLC now owns 17,499 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 12,854 shares in the last quarter. grace capital acquired a new stake in shares of Dermira in the 2nd quarter valued at $153,000. First Republic Investment Management Inc. acquired a new stake in shares of Dermira in the 2nd quarter valued at $221,000. Finally, Aperio Group LLC boosted its holdings in shares of Dermira by 126.5% in the 2nd quarter. Aperio Group LLC now owns 24,828 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 13,867 shares in the last quarter. Hedge funds and other institutional investors own 80.96% of the company’s stock.

About Dermira

Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.

Featured Story: How much money do you need to begin day trading?

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply